"Study of Clinical outcomes and serum concentration of Meropenem in acute kidney injury"

Study of Clinical outcomes and serum concentration of meropenem in patients with acute kidney injury treated with two different dosing regimens

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160412027346N5

Enrollment

Registered

2019-01-19

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney disease. Acute kidney failure

Interventions

Intervention 1: Intervention group: recieving Meropenem 1 gram three times a day. Intervention 2: Intervention group: recieving Meropenem with regulated dose based on daily creatinine level.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acute kidney injury Recepient of Meropenem Age over 18 year

Exclusion criteria

Exclusion criteria: History of chronic kidney disease Get chronic or emergency dialysis History of seizure History of allergy to beta-lactam Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Serum concentration of Meropenem. Timepoint: Measurement of serum concentration of Meropenem in half an hour before and one hour after infusion on three and fifth day of drug injection. Method of measurement: HPLC.	—

Secondary

Measure	Time frame
Clinical outcomes. Timepoint: Daily. Method of measurement: Clinical Pulmonary infection Score.;Serum creatinin. Timepoint: Daily. Method of measurement: Laboratory method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRezvan Hassanpour

Shahid Beheshti University of Medical Sciences

Hassanpour@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026